Editas Medicine appoints Bernadette Connaughton to Board of Directors

Editas Medicine, Inc.

Board expanded to add Bernadette Connaughton as independent director, effective October 26, 2021.
Appointed to Organization, Leadership and Compensation Committee; term until 2023 Annual Meeting.
Ms. Connaughton previously served as President Intercontinental at Bristol-Myers Squibb (1983-2017).
Director compensation: $40,000 annual cash retainer, $5,000 committee fee, and option for 24,732 shares vesting over 3 years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bernadette Connaughton

Independent Director

EDIT · Editas Medicine, Inc.

Effective: 2021-10-26
Filed: October 28, 2021, 7:59 PM ET

On October 26, 2021, the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Bernadette Connaughton as an independent director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bernadette Connaughton was appointed as Independent Director at Editas Medicine, Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

On October 26, 2021, the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Bernadette Connaughton as an independent director, effective immediately.

View on SEC.gov

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-21-013688

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.